September 4-7, 2018
Hynes Convention Center,
Boston, MA
the largest bioprocessing event bringing you the science, technologies and partners needed to accelerate promising biologics towards commercial success
More science. More new data. More case studies. BPI has you covered.
7 Tracks Cover the Entire BioProcessing Spectrum
Your registration for BPI provides you access to 225+ case studies and new data presentations across 7 concurrent tracks.
[NEW FOR 2018] Speed from Gene to Market
Gain the industry insights you need to accelerate speed and compress timelines to IND and BLA submissions.
[NEW for 2018] Bioprocessing 4.0 - The Path to Smart Manufacturing
Apply today's data, analytics, automation and technology to transform biologics manufacturing by reducing costs and increasing efficiencies & throughput
Cell Culture & Upstream Processing
Accelerate your product from early stage development to commercial-scale manufacturing.
Manufacturing Strategy
Reduce costs, increase manufacturing efficiency and remain flexible in your biomanufacturing operations.
Analytical & Quality
Ensure your products meet increasing analytical and quality regulations.
Drug Product, Fill-Finish & Formulations
Accelerate your drug substance towards a finished drug product.
The Brightest Minds in Bioprocessing
Our speakers represent today's leading scientists and executives who share innovative case studies and new data to help you improve integration, productivity and cost savings across the entire bioprocessing spectrum.
New for BPI 2018
VISIONARY KEYNOTE LINEUP
- Bob Langer, MIT
- Tina Larson, Achaogen
- Jason Walther, Sanofi
- Thomas Seewoester, Amgen
- Elsie DeBella, Momenta Pharmaceuticals
- E. Morrey Atkinson, Bristol-Myers Squibb
- Rebecca Sendak, Sanofi
TWO NEW CONFERENCE TRACKS
- Speed from Gene to Market
- Bioprocessing 4.0 – The Path to Smart Manufacturing
FIVE PRE-CONFERENCE SYMPOSIA
- Viral Clearance
- Process Intensification
- Cell Line Development
- PAT and Advanced Process Control
- Continuous Processing
TECHNOLOGY AND INNOVATION ROUNDTABLE
Identify, evaluate and discuss today's emerging bioprocess technologies that can help accelerate biologics towards commercial success.
KEY UPDATES FROM BPOG
- Technology Roadmap
- Drug Product Robustness Studies
- Real-Time Release
- Disposables 5-Year Plan
CELL & GENE THERAPY BIOPROCESSING & COMMERCIALIZATION
Your registration to BPI 2018 includes access to our co-located Cell & Gene Therapy Bioprocessing & Commercialization meeting.
Advance Your Drug Candidates Closer to Approval
The Most Innovative Science
Capitalize on 225+ case studies and new data presentations from global thought leaders to improve integration, productivity and cost savings across the entire bioprocessing spectrum.
The Largest Exhibition Devoted to Biomanufacturing
Accelerate your drug product to market by accessing innovative products and technologies from 160+ global exhibitors devoted to serving the biopharmaceutical manufacturing industry.
The Right Partners for You
Establish successful partnerships with 2000+ bioprocessing professionals made up of global innovators, suppliers, academia and associations who can help you achieve commercial success for your novel therapeutics.
Present at Scientific Poster
Share your company's new research by presenting a poster at BPI 2018. All posters are displayed in the exhibit & poster hall area throughout the event.
Please note that all poster presenters must be registered attendees. The deadline to submit your abstract is August 3, 2018.
Cell & Gene Therapy Bioprocessing & Commercialization
Your registration to BPI includes complimentary access to all of the main conference sessions of our co-located Cell & Gene Therapy Bioprocessing & Commercialization meeting.
Register today and transform innovative research to drive the future of cell & gene therapy manufacturing and commercialization.
Sponsorship & Exhibition Opportunities
Highlight your company's expertise to a global audience of 2000+ bioprocessing scientists and decision makers. A wide variety of options are available to accommodate your company's goals and budget.
“BPI is a great opportunity to connect with top professionals and share best practices to enable innovation across our industry.”
E. Morrey Atkinson, Ph.D.
Vice President, Internal Manufacturing for Biologics
Bristol-Myers Squibb
“I find the BPI conference to be a place where I can get reinvigorated about the science and technology that we perform every day. It provides a reminder that others not only learn from what you are sharing, but are inspired by it and provides you that same opportunity.”
Elsie DeBella
Vice President, Biologics Process and CMC Development, Pharmaceutical Sciences
Momenta Pharmaceuticals
“This is a great opportunity to understand the latest thinking behind accelerating product development within our industry.”
Rebecca A. Sendak, Ph.D.
US Head of BioPharmaceutics Development
Sanofi
“Connecting the world leaders in bioprocessing is an exciting opportunity for gaining momentum on helping patients with unmet medical needs.”
Daniel Heitmann, Ph.D.
Head Portfolio & Project, Integrated Biologics Profiling
Novartis Pharma AG, Switzerland
“I’m really looking forward to hearing from and speaking with my peers across the industry – I always come away from the event with fresh new ideas!”
Gene Lee, Ph.D.
Senior Director and US Site Head, Discovery and Development Technologies, Head, Protein & Cell Sciences/NBE
EMD Serono Research and Development Institute
Bioprocess Monitoring and Control Featured Report
The need for advanced control strategies for bioprocessing and biomanufacturing is growing, and several manufacturers already have leveraged new automation and software solutions for bioprocess monitoring and control. Authors discuss new approaches for process control that make use of increased computational power; advanced sensors, probes, and sampling technologies; and new software systems that can be applied to a wide range of operational modes (e.g., perfusion, continuous, and multicolumn platforms). Such technologies can be applied with single-use systems and within PAT and “machine learning” applications.
